Available a-synuclein PET tracers, particularly [18F]ACI-12589, have shown that it is feasible to image a-synuclein pathology via PET, and these tracers are expected to transform the way in which clinicians diagnose and manage conditions such as MSA and likely, the way clinical trials in MSA are performed. Here, SNCA is linked to multiple system atrophy.